Cargando…
Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis
BACKGROUND: Malignancies in the urinary tract and the kidney graft are quite common after kidney transplantation. In some selected cases tumours develop from donor-derived tissue. OBJECTIVES: We hypothesised that there is a clinical value to investigate donor/recipient origin in urologic malignancie...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491581/ https://www.ncbi.nlm.nih.gov/pubmed/36129920 http://dx.doi.org/10.1371/journal.pone.0271293 |
_version_ | 1784793305927647232 |
---|---|
author | Hellström, Vivan Tufveson, Gunnar Loskog, Angelica Bengtsson, Mats Enblad, Gunilla Lorant, Tomas |
author_facet | Hellström, Vivan Tufveson, Gunnar Loskog, Angelica Bengtsson, Mats Enblad, Gunilla Lorant, Tomas |
author_sort | Hellström, Vivan |
collection | PubMed |
description | BACKGROUND: Malignancies in the urinary tract and the kidney graft are quite common after kidney transplantation. In some selected cases tumours develop from donor-derived tissue. OBJECTIVES: We hypothesised that there is a clinical value to investigate donor/recipient origin in urologic malignancies in renal transplant recipients. METHODS: In this retrospective study, including patients transplanted between the years 1969 and 2014 at Uppsala University Hospital, Sweden, 11 patients with malignancies in urinary tract and 4 patients with malignancies in kidney transplants were investigated. Donor/recipient origin of tumour tissue was analysed by polymerase chain reaction (PCR) of human leucocyte antigen (HLA) genotypes or by fluorescence in situ hybridization (FISH analysis) of sex chromosomes. HLA genotype and sex chromosomes of the tumour were compared to the known HLA genotype and sex chromosomes of recipient and donor. RESULTS: Three of ten cancers in the urinary tract and three of four cancers in the kidney transplants were donor-derived. CONCLUSIONS: We suggest that urologic malignancies in renal transplant recipients can be investigated for transplant origin. In addition to conventional therapy the allograft immune response against these tumours can be valuable to treat donor-derived cancers. |
format | Online Article Text |
id | pubmed-9491581 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-94915812022-09-22 Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis Hellström, Vivan Tufveson, Gunnar Loskog, Angelica Bengtsson, Mats Enblad, Gunilla Lorant, Tomas PLoS One Research Article BACKGROUND: Malignancies in the urinary tract and the kidney graft are quite common after kidney transplantation. In some selected cases tumours develop from donor-derived tissue. OBJECTIVES: We hypothesised that there is a clinical value to investigate donor/recipient origin in urologic malignancies in renal transplant recipients. METHODS: In this retrospective study, including patients transplanted between the years 1969 and 2014 at Uppsala University Hospital, Sweden, 11 patients with malignancies in urinary tract and 4 patients with malignancies in kidney transplants were investigated. Donor/recipient origin of tumour tissue was analysed by polymerase chain reaction (PCR) of human leucocyte antigen (HLA) genotypes or by fluorescence in situ hybridization (FISH analysis) of sex chromosomes. HLA genotype and sex chromosomes of the tumour were compared to the known HLA genotype and sex chromosomes of recipient and donor. RESULTS: Three of ten cancers in the urinary tract and three of four cancers in the kidney transplants were donor-derived. CONCLUSIONS: We suggest that urologic malignancies in renal transplant recipients can be investigated for transplant origin. In addition to conventional therapy the allograft immune response against these tumours can be valuable to treat donor-derived cancers. Public Library of Science 2022-09-21 /pmc/articles/PMC9491581/ /pubmed/36129920 http://dx.doi.org/10.1371/journal.pone.0271293 Text en © 2022 Hellström et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Hellström, Vivan Tufveson, Gunnar Loskog, Angelica Bengtsson, Mats Enblad, Gunilla Lorant, Tomas Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis |
title | Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis |
title_full | Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis |
title_fullStr | Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis |
title_full_unstemmed | Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis |
title_short | Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis |
title_sort | donor-derived urologic cancers after renal transplantation: a retrospective non-randomized scientific analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491581/ https://www.ncbi.nlm.nih.gov/pubmed/36129920 http://dx.doi.org/10.1371/journal.pone.0271293 |
work_keys_str_mv | AT hellstromvivan donorderivedurologiccancersafterrenaltransplantationaretrospectivenonrandomizedscientificanalysis AT tufvesongunnar donorderivedurologiccancersafterrenaltransplantationaretrospectivenonrandomizedscientificanalysis AT loskogangelica donorderivedurologiccancersafterrenaltransplantationaretrospectivenonrandomizedscientificanalysis AT bengtssonmats donorderivedurologiccancersafterrenaltransplantationaretrospectivenonrandomizedscientificanalysis AT enbladgunilla donorderivedurologiccancersafterrenaltransplantationaretrospectivenonrandomizedscientificanalysis AT loranttomas donorderivedurologiccancersafterrenaltransplantationaretrospectivenonrandomizedscientificanalysis |